Express Mail Label No.

PTO/SB/05 (03-01)

Approved for use through 10/31/2002 OMB 0651-0032 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

R0079C-REG Attorney Docket No. First Inventor Becker, et al **QUINAZOLONE DERIVATIVES AS ALPHA 1A/B** Titl е ADRENERGIC RECEPTOR ANTAGONISTS

ET648477127US

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

APPLICATION ELEMENTS					Assistant Commissioner for Patents Box Patent Application						
See MPEP chapter 600 concerning utility patent application contents.					Washington, DC 20231						
2. \(\begin{array}{c} \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Fee Transmittal Form (e.g., PTO/SB/17) Submit an onginal and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. Specification [Total Pages 98] preferred arrangement set forth below) Descriptive title of the Invention Cross Reference to Related Applications Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, or a computer program listing appendix			7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATIONS PARTS							
	- Background of the Invention										
-	Brief Description Detailed Descript Claim(s)				9. Assignment Papers (cover sheet & document(s)) 10. 37 C.F.R.§3.73(b) Statement Power of (when there is an assignee) Attorney						
- Abstract of the Disclosure						11. English Translation Document (if applicable)					
4. Drawing(s) (35 U.S.C.113) [Total Sheets] 5. Oath or Declaration [Total Pages 3]					12. ☐ Information Disclosure ☐ Copies of IDS Statement (IDS)/PTO-1449 Citations 13. ☐ Preliminary Amendment						
 a. Newly executed (copy) b. Copy from a prior application (37 CFR 1.63 (d)) 							-		(MPEP 503)		
b. 📙		rior application (37) ation/divisional with			15. 🗆			ecifically ite			
i. 🗀	DELETION	OF INVENTOR(S	3)		15.	15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)					
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).					16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.						
6.	olication Data S	heet. See 37 CFR	1.76		17. Other:						
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Of prior application No: First application information: Examiner Group / Art Unit:											
 Claim for Benefit of Provisional Application(s): This application claims the benefit under Title 35 U.S.C. 119(e) of U.S. Provisional Application No. 60/259,337, filed January 2, 2001, and 60/325,267, filed September 27, 2001. 											
			17. C	ORRESPON	DENCE AL	DDRESS					
☑ Customer Number or Bar Code Label or ☐ Correspondence address below											
Name	Rohan Peries 24372										
	ROCHE BIOSCIENCE PATENENT & TRADMARK OFFICE										
Addrose	Patent Law	Patent Law Dept., M/S A2-250									
Address	3401 Hillvie										
City	Palo Alto	o Alto State			CA		Zip	Code	94304		
Country	U.S.A. Telephone		hone	650/ 354-7540 Fax			Fax	650/ 855-5322			
Name (Print/Type)		GLORIA PFISTER			Registra	Registration No. (Attorney/Agent)			45,642		
Signature		کے	3 3	Pista	·			Date	01/02/02		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

EEE TO A MONITTAL	Complete if Known				
FEE TRANSMITTAL	Application Number	New Application			
for FY 2002	Filing Date				
	First Named Inventor	Becker, et al.			
Patent fees are subject to annual revision.	Examiner Name				
	Group / Art Unit				

TOTAL AMOUNT OF PAYMENT (\$) 1,082.00	Attor	ney Docket	No.	ROC	79C-REG		
METHOD OF PAYMENT (check one)			FEE C				
The Commissioner is hereby authorized to charge indicated fees, to charge any additional fees that may be required, or to credit any overpayments to:		DITIONAL I Large Entity		Small Entity			
Deposit	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid	
Account 18-1700	105	130			Surcharge - late filing fee or oath		
Number	127	50			Surcharge - late provisional filing fee or cover sheet.		
Deposit Roche Bioscience	139	130			Non-English specification		
Account 3401 Hillview Avenue	147 112	2,520			For filing a request for reexamination		
	112	920*			Requesting publication of SIR prior to Examiner action		
Charge Any Additional Fee Required Under 37 CFR 1 16 and 1.17	113	1,840*			Requesting publication of SIR after Examiner action		
Applicant claims small entity status. See 37 CFR 1.27	115	110			Extension for reply within first month		
2. Payment Enclosed:	116	400			Extension for reply within second month		
☐ Check ☐ Credit card ☐ Money ☐ Other	117	920			Extension for reply within third month		
Order	118	1,440			Extension for reply within fourth		
FEE CALCULATION	1				month		
1. BASIC FILING FEE	128 119	1,960			Extension for reply within fifth month		
Large Entity Small Entity	120	320 320			Notice of Appeal		
Fee Fee Fee Fee Description Code (\$) Code (\$)	121	280			Filing a brief in support of an appeal Request for oral hearing		
Code (\$) Code (\$) Fee Paid 101 740 Utility filling fee 740.00	138	1,510			Petition to institute a public use proceeding		
106 330 Design filing fee	140	110			Petition to revive – unavoidable		
107 510 Plant filing fee	141	1,280			Petition to revive – unintentional		
108 740 Reissue filing fee	142	1,280			Utility issue fee (or reissue)		
114 160 Provisional filling	143	460			Design issue fee		
fee	144	620			Plant issue fee		
SUBTOTAL (1) (\$) 740	122	130			Petitions to the Commissioner		
(\$) 740	123	50			Processing fee under 37 CFR 1.17 (q)		
2. EXTRA CLAIM FEES Extra Fee from Fee	126	180			Submission of Information Disclosure Stmt		
Total Claims 39 -20 ** = 19 X 18 = 342	581	40			Recording each patent assignment per property (times number of properties)		
ndependent Claims 1 -3 ** = 0 X 84 = 0	146	740			Filing a submission after final rejection (37 CFR § 1.129(a))		
Multiple X = 0	149	740			For each additional invention to be examined (37 CFR § 1.129(b))		
Large Entity Small Entity	179	740		F	Request for Continued Examination (RCE)		
Fee Fee Fee Fee Code (\$) Code (\$) Fee Description	169	900			Request for expedited examination		
103 18 Claims in excess of 20					of a design application		
102 84 Independent claims in excess of 3					•		
104 280 Multiple dependent claim, if not paid	Other fe	ee (specify)					
109 84 ** Reissue independent claims over original patent		(4)			L		
110 18 *** Reissue claims in excess of 20 and over original patent	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0						
SUBTOTAL (2) (\$) 342.00							
**or number previously paid, if greater; For Reissues, see above							
SUBMITTED BY Complete (if applicable)							
Name (Print/Type) Gloria Pfister Registration No. Attorney/Age	ent)	45,642	Te	elephone	650/ 354-7540		
Signature 91/02/0						S	